Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2010 2
2012 6
2013 2
2014 4
2015 11
2016 26
2017 39
2018 27
2019 27
2020 37
2021 40
2022 40
2023 35
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Results by year

Filters applied: . Clear all
Page 1
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo). RESULTS: A prima …
The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of …
Selexipag.
[No authors listed] [No authors listed] 2016 Nov 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 Nov 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644051 Free Books & Documents. Review.
Selexipag is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH). Selexipag has been associated with a low rate of serum enzyme elevations during therapy, but has yet to …
Selexipag is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary …
Selexipag for the treatment of pulmonary arterial hypertension.
Genecand L, Wacker J, Beghetti M, Lador F. Genecand L, et al. Expert Rev Respir Med. 2021 May;15(5):583-595. doi: 10.1080/17476348.2021.1866990. Epub 2020 Dec 31. Expert Rev Respir Med. 2021. PMID: 33382345 Review.
AREAS COVERED: We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis. ...However, …
AREAS COVERED: We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy …
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
Ogo T, Shimokawahara H, Kinoshita H, Sakao S, Abe K, Matoba S, Motoki H, Takama N, Ako J, Ikeda Y, Joho S, Maki H, Saeki T, Sugano T, Tsujino I, Yoshioka K, Shiota N, Tanaka S, Yamamoto C, Tanabe N, Tatsumi K; Study Group. Ogo T, et al. Eur Respir J. 2022 Jul 7;60(1):2101694. doi: 10.1183/13993003.01694-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34824052 Free PMC article. Clinical Trial.
CONCLUSION: Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH....
CONCLUSION: Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity …
Selexipag for pulmonary arterial hypertension.
[No authors listed] [No authors listed] Aust Prescr. 2021 Apr;44(2):67-68. doi: 10.18773/austprescr.2021.007. Epub 2021 Feb 4. Aust Prescr. 2021. PMID: 33911339 Free PMC article. Review. No abstract available.
An evaluation of selexipag for the treatment of pulmonary hypertension.
Panagiotidou E, Boutou A, Pitsiou G. Panagiotidou E, et al. Expert Opin Pharmacother. 2021 Jan;22(1):29-36. doi: 10.1080/14656566.2020.1812579. Epub 2020 Aug 31. Expert Opin Pharmacother. 2021. PMID: 32867545 Review.
INTRODUCTION: Selexipag is a first-in-class, oral, long-acting, selective, non-prostanoid agonist of the prostacyclin receptor (IP receptor), indicated for the treatment of symptomatic adult pulmonary arterial hypertension (PAH). ...The TRITON study failed to demonstrate a …
INTRODUCTION: Selexipag is a first-in-class, oral, long-acting, selective, non-prostanoid agonist of the prostacyclin receptor (IP re …
Selexipag and the pulmonary hypertension continuum.
Maeder MT. Maeder MT. Eur J Heart Fail. 2022 Jan;24(1):215-218. doi: 10.1002/ejhf.2387. Epub 2021 Dec 12. Eur J Heart Fail. 2022. PMID: 34816552 Free article. No abstract available.
Selexipag: A Review in Pulmonary Arterial Hypertension.
Duggan ST, Keam SJ, Burness CB. Duggan ST, et al. Am J Cardiovasc Drugs. 2017 Feb;17(1):73-80. doi: 10.1007/s40256-016-0209-9. Am J Cardiovasc Drugs. 2017. PMID: 27988834 Review.
Selexipag (Uptravi()) is an orally active, first-in-class, selective prostacyclin IP receptor agonist. ...Thus, selexipag extends the treatment options available in patients with PAH....
Selexipag (Uptravi()) is an orally active, first-in-class, selective prostacyclin IP receptor agonist. ...Thus, selexipag exte …
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Galiè N, et al. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. Adv Ther. 2022. PMID: 34727317 Free PMC article. Clinical Trial.
RESULTS: Overall, 953 patients in GRIPHON and GRIPHON OL were treated with selexipag. At the time of selexipag initiation, 81.2% of patients were receiving background PAH therapy. ...A large proportion of the population was receiving background therapy at selexip …
RESULTS: Overall, 953 patients in GRIPHON and GRIPHON OL were treated with selexipag. At the time of selexipag initiation, 81. …
Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
Baker WL, Darsaklis K, Singhvi A, Salerno EL. Baker WL, et al. Ann Pharmacother. 2017 Jun;51(6):488-495. doi: 10.1177/1060028017697424. Epub 2017 Feb 1. Ann Pharmacother. 2017. PMID: 28478717 Review.
DATA SYNTHESIS: Single phase II and phase III trials have been published evaluating selexipag in patients with PAH. In 43 patients, the phase II trial showed that selexipag significantly reduced pulmonary vascular resistance by 30% versus placebo ( P = 0.0045) and i …
DATA SYNTHESIS: Single phase II and phase III trials have been published evaluating selexipag in patients with PAH. In 43 patients, t …
279 results